Moberg Pharma Ab · OMXSTO:MOB

Moberg Pharma Ab — Redeye corporate presentation, September 2014

36 slides from Moberg Pharma Ab's conference presentation, Sep 24, 2014

  1. Slide 1: Moberg Pharma AB

    Moberg Pharma AB Combining Commercial and Innovation Excellence to provide unique products in underserved markets Corporate Presentation – Redeye, September 24, 2014 Peter Wolpert, CEO and Founder 0

  2. Slide 2: Disclaimer

    Disclaimer Statements included herein that are not historical facts are forward-looking statements. Such forward- looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Moberg Pharma’s results could

  3. Slide 3: Content

    CONTENT COMBINING COMMERCIAL AND INNOVATION EXCELLENCE  Presentation of MOB-015 Phase II results  Business update 2 2

  4. Slide 4: MOB015 Phase II results

    MOB015 Phase II results 3

  5. Slide 5: MOB-015B Phase II study

    MOB-015B Phase II study Study design Open-label phase II study in onychomycosis conducted at the Sahlgrenska University Hospital Patients received MOB-015 once daily for 12 months. Last follow-up was at 15 months from inclusion Coordinating Investigator: Professor Jan Faergemann Primary efficacy var

  6. Slide 6: Excellent Phase II results

    Excellent Phase II results FINAL RESULTS AT 15 MONTHS 54% 29% MYCOLOGICAL CURE MYCOLOGICAL CURE AND EXCELLENT CLINICAL IMPROVEMENT OR CURE 5 Source: Moberg Pharma data on file from MOB-015 phase II study 5

  7. Slide 7: MOB015 phase II results are superior to topical drugs on the market

    MOB015 phase II results are superior to topical drugs on the market without the safety issues of oral therapy Mycological cure Active Product Company Form at 6 months at 12/15 Comment months Terbinafine MOB-015 Moberg Pharma Topical 40%1) 54% 25-75% affected Ciclopirox Penlac Sanofi Topical - 29-36%

  8. Slide 8: Anacor/Sandoz deal – July 2014

    CONFIDENTIAL Anacor/Sandoz deal – July 2014 Total Deal Value estimated to NPV of 270 m$ (if no exercise of repurchase option) Upfront 65 m$ (whereof 25 m$ by Jan 2015) Payment 2016 45 m$ 50% of gross profits 2017-2025 Source: Anacor press release, MP analysis: estimate at least 100 m$ gross profit p

  9. Slide 9: Photos from MOB-015 phase II

    CONFIDENTIAL Photos from MOB-015 phase II 8

  10. Slide 10: Patient photos

    PatientID:0/ -1eD > Besék: vu 2 Datum: 20/4 -0y-/Y PHARMA

  11. Slide 11: Patient photos

    PatientID: 0/- /oDé | Besék: vv Datum: 2¢/ 4-04-28 PHARMA

  12. Slide 12: Patient photos

    a aaa PatientID: Soi.-23 Besok: t Datum: 13O2(4% PHARMA

  13. Slide 13: Patient photos

    PatientID: Gl = LOL Ta Besok: Vv & Datum: 4725 <F

  14. Slide 14: Patient photos

    PatientID: SO; - ( & ‘ PatientiID: O/ Besdk: Var Datum: /v2 5 27 PHARMA

  15. Slide 15: Patient photos

    PatientID:77—75 Besék: Ww S Datum: /¥p é/? 20

  16. Slide 16: Patient photos

    PatientID: Besok: PHARMA

  17. Slide 17: Patient photos: no improvement

    No improvement Patient! Bes6k: Datum: 20 13-01-29 PatientiD: 0 / Besok: vu Datum: sve PHARMA

  18. Slide 18: Patient photos: little improvement

    Pat nr 1011 Little improvement 17

  19. Slide 19: MOB-015 next steps

    MOB-015 next steps  Strategy to select partner for continued development and commercialization  Potential partners identified  Partner discussions ongoing 18 18

  20. Slide 20: Business Update

    Business Update

  21. Slide 21: 2014 TV commercial in the Nordics

    2014 TV commercial in the Nordics 20 20

  22. Slide 22: Moberg Pharma

    Moberg Pharma COMBINING COMMERCIAL AND INNOVATION EXCELLENCE  Net Sales grew to 178 MSEK (TTM, Q214) - U.S. OTC Sales operations - Products sold in 40+ countries - 30 employees in Sthlm and NJ  Focus in OTC/Dermatology/Topicals - Leading U.S. OTC SKU in Nail Fungus - Superior PII data for MOB015 

  23. Slide 23: 2014 Highlights

    2014 Highlights #1 with 25% 58% U.S. Market share last 4w Stronger claims Growth in Direct sales H114 Expanded indication for Nalox in EU 21% 60 million SEK raised in directed share issue EBITDA margin for Commercial operations in H114 BUPI - Pipeline boost Acquisition of phase II asset Strong Ph II

  24. Slide 24: Consecutive quarters of sales growth

    17 consecutive quarters of sales growth Product Sales, TTM, MSEK 200 MSEK 175 150 125 100 75 50 25 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2010 2010 2010 2010 2011 2011 2011 2011 2012 2012 2012 2012 2013 2013 2013 2013 2014 2014 23 23

  25. Slide 25: Majority of revenue from direct OTC sales

    Majority of revenue from direct OTC sales – Strong contribution to earnings from both channels Distribution of revenue, Jan – June 2014 JointFlex Other RoW Sales via 12% 12% 4% distributors Europe 32% Kerasal 22% 16% Nalox/ Direct OTC Kerasal Nail Americas Sales 68% 60% 74% Channels Products Geograp

  26. Slide 26: Rapid increase in sales and EBITDA

    Rapid increase in sales and EBITDA (MSEK) 157 112 106 Milestones 56 Product Sales Net Sales 2011 2012 2013 2014 H1 13 14 13 EBITDA EBITDA -8 -8 -13 EBITDA excluding -16 milestone payments -29 25 25

  27. Slide 27: Commercial EBITDA margin exceeding 20% and EBITDA increased to 14% in H1

    Commercial EBITDA margin exceeding 20% and EBITDA increased to 14% in H1 Jan-Jun Jan-Jun Full-year (MSEK) 2014 2013 2013 Revenues 105.5 83.4 157.4 - Product Sales 103.7 83.4 152.6 - Milestones 1.8 - 4.8 EBITDA 14.4 -7.3 -8.0 EBITDA-margin 14% neg neg Operating profit 10.5 -10.3 -14.1 Earnings after

  28. Slide 28: Progress in Commercial Operations & Innovation Engine

    Progress in Commercial Operations & Innovation Engine

  29. Slide 29: Significantly faster growth than the market

    Significantly faster growth than the market Organic growth 2014 H1 (Value), percent Growth driver 31%  Combination of Brand and IP equity: 5% Moberg U.S. U.S. OTC market 28 28

  30. Slide 30: Acquired mature brands contribute to cash-flow

    Acquired mature brands contribute to cash-flow • Domeboro is a astringent solution that provides fast, soothing itch relief for skin irritations - Brand update - Skin Center launched - Reminding Dermatologists - Line extension opportunities • Vanquish provides strong headcache relief with lower safe

  31. Slide 31: Domeboro - Brand modernization

    CONFIDENTIAL Domeboro - Brand modernization New web - Skin Care Center 30 30

  32. Slide 32: Distributor Sales well positioned for further growth

    Distributor Sales well positioned for further growth Nalox™/Kerasal Nail™  10% growth in Europe – implementation of new stronger claims only started.  Potential for further growth in 2015  Strong sales in Canada as response to launch of consumer advertising,  Market leader with 25% market share

  33. Slide 33: Innovation engine

    Innovation engine  8 patent families >100 - MOB015 – entering licensing - BUPI – Ph II expected Sept – Q115 - Kerasal Nail+/Nalox+  Focus to strengthen OTC pipeline BD OPPORTUNITIES EVALUATED IN LAST 12 MONTHS Acquisitions/inlicensing  Focus on OTC assets for U.S. market 3 ACQUISITIONS LAST 21 Co

  34. Slide 34: The Share last 3 years

    The Share last 3 years (Sept 19 2014) Analysts  Klas Palin, Redeye  Christian Lee, Remium  Additional coverage expected H2 2014 33 33

  35. Slide 35: Additional institutional investors after share issue in May

    CONFIDENTIAL Additional institutional investors after share issue in May Shareholders No of shares Capital and votes, % ÖSTERSJÖSTIFTELSEN 2 248 478 16,1 SIX SIS AG, W8IMY 890 645 6,4 JPM CHASE NA (Altaris Capital Partners) 825 652 5,9 BURE EQUITY AB (PUBL) 811 151 5,8 FÖRSÄKRINGSAKTIEBOLAGET, AVANZ

  36. Slide 36: Focus next 12 months

    Focus next 12 months COMBINING COMMERCIAL AND INNOVATION EXCELLENCE  Improving EBITDA!  Fuel strong U.S growth - K-Nail and Neurocream launch - Line extensions and new SKUs  Grow Distributor Sales - EU: Extended indication - China registration, SE Asia, Mena  BD focus - US OTC products  MOB-015

Moberg Pharma — Redeye corporate presentation, September 2014 on 6ix